Twitter | Search | |
Multiple Myeloma Hub
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology
3,233
Tweets
2,250
Following
3,730
Followers
Tweets
Multiple Myeloma Hub 6h
💊 KRd plus auto-SCT shows promising activity in a phase II trial for newly diagnosed MM .📖 Read more here
Reply Retweet Like
Multiple Myeloma Hub Sep 22
📢Don't miss out on the latest research in multiple delivered direct to your inbox. Sign up today for the bi-monthly newsletter!
Reply Retweet Like
Multiple Myeloma Hub retweeted
Hans Scheurer Sep 21
Emerging immunotherapies in multiple myeloma - Great overview treatment developments in
Reply Retweet Like
Multiple Myeloma Hub Sep 21
🦠Christine Spencer, and , discuss how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as GvHD. Watch our animated video with them during
Reply Retweet Like
Multiple Myeloma Hub retweeted
Graham jackson Sep 18
Although this study does not meet its primary end point there is soo much positive data in this important trial
Reply Retweet Like
Multiple Myeloma Hub Sep 18
Thanks for joining us during ! Some final opinions heard many times this week: the high hopes of new therapies for , the value of awareness & early diagnosis, and the need for international collaboration to keep going forward! Next ➡️ ISA2022 in Heidelberg🇩🇪
Reply Retweet Like
Multiple Myeloma Hub Sep 18
CONGRESS | | CAEL-101 is a monoclonal IgG1 Ab that directly binds to a conformational epitope present on both kappa & lambda light-chain amyloid fibrils. Phase Ia/Ib trial showed CAEL-101 safety and long-term organ responses in relapsed patients with AL
Reply Retweet Like
Multiple Myeloma Hub Sep 18
CONGRESS |  | Will venetoclax be a new effective option for relapsed AL ? We'll need a larger controlled clinical trial to confirm that, but see below the promising results of a retrospective study presented by : 78% ≥VGPR in pts with t(11;14).
Reply Retweet Like
Multiple Myeloma Hub Sep 18
Replying to @MM_Hub
The results of this safety run-in enabled proceeding to patient enrollment in the randomized part of the study. The primary analysis was presented recently at Read a summary here:
Reply Retweet Like
Multiple Myeloma Hub Sep 18
CONGRESS | | After a median follow-up of 22.9 months of the safety run-in cohort from the ANDROMEDA trial, daratumumab + CyBorD shows a continuous improvement in hematologic and organ response rates in AL . Presented by
Reply Retweet Like
Multiple Myeloma Hub Sep 18
Replying to @MayoHemeOnc
Review our article on the Hub covering these results, presented previously at by Angela Dispenzieri from
Reply Retweet Like
Multiple Myeloma Hub Sep 18
CONGRESS | | Tourmaline-AL1 trial did not meet its primary endpoint (ORR), but significantly improved clinically relevant variables such as CR rate, organ response, or time to next treatment. Thus, ixa could be considered for pts with AL and limited options.
Reply Retweet Like
Multiple Myeloma Hub Sep 18
CONGRESS | | Terri Parker from presented the ongoing phase II of isatuximab in relapsed AL . To date, isa was well-tolerated in patients previously treated with bortezomib (89%) and/or SCT (47%).
Reply Retweet Like
Multiple Myeloma Hub Sep 18
💊 Frequently, lenalidomide dosing needs to be reduced due to hematologic toxicities. Roland Fenk from published new guidelines based on a phase III trial to optimize len maintenance therapy after auto-SCT
Reply Retweet Like
Multiple Myeloma Hub Sep 17
CONGRESS | | Eli Muchtar presented the validation of the new graded organ response criteria. This international collaborative study confirmed the association of cardiac, renal, and hepatic depth of response with the survival of patients with AL
Reply Retweet Like
Multiple Myeloma Hub retweeted
Jaimal Kothari Sep 16
Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care | Haematologica great work from our cancer pharmacist Faouzi (et al) looking at infections in this group of MM pts
Reply Retweet Like
Multiple Myeloma Hub Sep 16
| At , around 70% of pts with AL are ASCT candidates. But ≈12% of non-eligible patients improved their performance & organ involvement with a borte-based regimen & could undergo SCT, which significantly improved their outcomes. By MT Cibeira
Reply Retweet Like
Multiple Myeloma Hub Sep 16
CONGRESS | | E Kastritis et al. evaluated the significance of early response and early initiation of salvage therapy (for pts in <VGPR). In AL , a rapid (<1m) and deep response (≥VGPR) is associated with better survival➡️start with the most effective therapy
Reply Retweet Like
Multiple Myeloma Hub Sep 16
CONGRESS | | It's been previously reported the relative safety of digoxin in carefully selected patients with ATTR and AL cardiac . Check out & 's experience, reporting digoxin-related AEs in 12% of patients. By JP Donnelly
Reply Retweet Like
Multiple Myeloma Hub retweeted
Francesco Maura Sep 15
Excited to see our lab last paper on multiple myeloma structural variants published in : . A terrific effort at with
Reply Retweet Like